Chimerix Acquires Library of Potential Antiviral, Oncology Compounds
The company also obtained an option on intellectual property associated with the compounds.
The library includes compounds targeting antiviral and oncology targets. It was developed by Leroy Townsend, a professor of medicinal chemistry at Michigan.
Financial terms were not disclosed.
Chimerix will use the compounds from the antiviral library and its technology platform for drug development. The company said it intended to license the oncology lead candidates.
The lead compound under development at Chimerix is an oral treatment for smallpox and the complications from smallpox vaccine. The company was launched in 2002.
Chimerix: www.chimerix.com...Copyright 2013 by Capitol Broadcasting Company. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.
Please log in or register to view WRALTechWire Insider content
Please Log In to add a comment.